Ticker

Newly Issued Patent Expands Company's Neural Sensing Technology Platform into Large Urology Market Affecting Approximately 37 Million Americans THE WOODLANDS, TX, July 15, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, announced today that the United States Patent and Trademark Office…

THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor ("Investor") for the immediate exercise of certain outstanding warrants that the Company issued on November 19, 2025 (the…

THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on November 19, 2025 (the…

Autonomix Medical Inc (NASDAQ:AMIX) has been granted a new patent strengthening its neural sensing intellectual property, the company said, adding to a portfolio it ties to what it called the multi-billion-dollar denervation market. Autonomix said the patent grant covers its neural sensing technology and reinforces its intellectual property position.

Autonomix Medical Inc (NASDAQ:AMIX) has been granted a new patent strengthening its neural sensing intellectual property, the company said, adding to a...